First patient at Moffitt dosed in Phase 1b/2 breast trial
Filed with ASX · · 2 pages · English
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Appendix 4E and 2016 Annual Report
- USPTO Grants Allowances for Two PTX-200 Patents
- Change to exercise price of options
- June 2016 Appendix 4C - Quarterly
- Yale Joins PTXs Phase 1b/2 AML Clinical Trial
Later from Prescient Therapeutics
- September 2016 Appendix 4C - Quarterly
- Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
- First Patient Dosed on Phase 1b/2 AML Trial
- December 2016 Appendix 4C - Quarterly
- First Cohort Successfully Completed in Phase 1b/2 AML Trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics